March 2026 Research Update

This month included one real-world study that looked at adding a non-Fabry medicine on top of Fabry-specific therapy, with a focus on heart and kidney measures over 12 months. The main pattern was reassuring short-term safety in this group, alongside small changes in certain measurements that differed by subgroup. Because the study compared patients to their own prior year rather than to a separate control group, the results are best read as an early signal rather than proof of benefit. [1]

In 48 adults with Fabry disease already on Fabry-specific therapy, starting an SGLT2 inhibitor was followed by no treatment-related adverse events and no Fabry-associated clinical events reported over the next year. In men, the yearly drop in kidney function (eGFR) slowed compared with the year before, and left ventricular ejection fraction (a measure of how well the heart pumps) increased slightly, with a bigger change noted in those who started with lower ejection fraction. Females were reported to remain clinically stable over the same period. [1]

For patients and caregivers, this adds early human data about what happened after an SGLT2 inhibitor was added to existing Fabry care in routine practice. What became clearer is that, in this 12-month window and this specific group, no new safety problems were reported and some heart and kidney measurements shifted in a favorable direction for some men. What remains uncertain is whether these changes were caused by the added medicine, how durable they are beyond 1 year, and which Fabry subgroups might see similar patterns in other settings. [1]

Several studies this month tried to sharpen how cardiac involvement in Fabry disease is detected or tracked, and they point in a similar direction: single tests rarely tell the whole story. Blood-protein patterns and hormone-like markers showed links to cardiac involvement, while heart imaging patterns sometimes overlap with other diseases and can be misread. Taken together, these studies add detail to the idea that Fabry heart assessment may require combining multiple clues rather than relying on one scan pattern or one lab value. [2] [3] [4] [5]

One observational study used a broad blood-protein screen and reported a 10-protein set that separated Fabry patients with cardiovascular disease from those without it. The same work also reported that its protein signature could distinguish Fabry patients from non-Fabry controls with high accuracy, although performance varied depending on the computer-modeling approach used. This suggests blood proteins might eventually help flag Fabry-related heart involvement, but the study was exploratory and needs confirmation in other patient groups. [2]

A separate longitudinal study followed adiponectin and leptin (hormone-like proteins related to metabolism) alongside a heart stress marker (NT-proBNP) and heart muscle imaging findings. Higher adiponectin tracked with higher NT-proBNP and with imaging signs of Fabry-related heart changes such as thickened heart muscle, low T1 values, and scarring, especially among people receiving Fabry-specific therapy. Over long follow-up, adiponectin, leptin, and standard cholesterol and triglyceride levels were reported as generally stable. [3]

Two imaging-focused papers highlighted that certain scan patterns can overlap between diseases. A systematic review found that a strain pattern called relative apical sparing was more pronounced in cardiac amyloidosis than in other heart conditions, and Fabry disease was included among the non-amyloid comparison groups, meaning this pattern is not specific to amyloidosis alone. A separate single-patient report showed intense heart uptake on a bone scan in Fabry disease, which could look like cardiac amyloidosis on that test. [4] [5]

For patients, these studies mainly add understanding about why heart testing in Fabry can be complicated and why results may need careful interpretation. What became clearer is that some blood markers (like adiponectin or protein panels) may line up with cardiac involvement, while certain imaging patterns can also appear in other conditions and may sometimes be misleading. What remains uncertain is which of these blood markers will hold up in larger, independent studies and whether they will become part of routine monitoring, since the current evidence is exploratory. [2] [3] [4] [5]

This month added practical information about how Fabry disease can be found earlier and how measurements can be made more accurate, especially in settings where tests can be missed or distorted. Across these studies, the shared message is that targeted evaluation and well-run systems can shorten delays, but lab methods and look-alike findings can complicate diagnosis. The studies range from small series to single cases, so they show what is possible rather than what will happen for everyone. [6] [7] [8] [9]

In a small prospective series of five children, a multidisciplinary team approach was reported to shorten time to diagnosis compared with families' earlier diagnostic journeys, and it enabled family screening that found an affected but asymptomatic sibling. All five started agalsidase alpha (an enzyme replacement therapy) with no infusion-related adverse events reported, and 1-year follow-up described symptom improvement along with lower Lyso-GL-3 (a blood marker linked to Fabry disease activity). The report also described coordinated pain management and psychosocial support as part of care. [6]

Two papers focused on pitfalls in testing and how to reduce them. In six people on long-term migalastat, residual drug in dried blood spot samples was shown to interfere with the alpha-GAL activity test, and filtering the sample increased and stabilized the measured enzyme activity in most samples. In a three-generation family report, targeted manual urine microscopy found mulberry cells and bodies that routine automated or non-targeted review missed, prompting genetic confirmation and identification of affected relatives, and the mulberry cell counts tracked with severity and fell with enzyme replacement therapy in the index case. [7] [8]

One case report showed the opposite problem: Fabry-like kidney biopsy findings do not always mean Fabry disease. A woman with two other kidney diseases had Fabry-like "zebra bodies" on electron microscopy, but normal alpha-galactosidase A activity and negative genetic testing, and Fabry disease was ruled out. This case highlights that some biopsy patterns can mimic Fabry and need confirmation with enzyme and genetic testing. [9]

For patients and caregivers, these studies are most relevant to understanding why some people get diagnosed quickly while others face delays, and why results sometimes need repeat or specialized testing. What became clearer is that organized care pathways and targeted review (such as careful urine microscopy when Fabry is suspected) can uncover cases that would otherwise be missed, and that some treatments (like migalastat) can affect how lab tests read unless the method accounts for it. What remains uncertain is how widely these approaches can be implemented across different clinics and countries, and how often these specific testing pitfalls occur in everyday practice. [6] [7] [8] [9]

Laboratory and early-stage human biology studies this month added more detail to the idea that Fabry disease involves more than storage of lipids alone, including inflammation and disrupted cellular cleanup processes. Another study worked on improving how a gene therapy approach might deliver and release the missing enzyme in a mouse model. These studies do not predict near-term outcomes for patients, but they help explain disease processes and test ideas that could shape future treatments or biomarkers. [10] [11] [12]

In 12 presymptomatic boys identified through newborn screening, blood tests showed higher levels of inflammatory signals (including IL-1beta and TNF-alpha in most participants) and lower levels of several autophagy-related markers (autophagy is a cell's recycling system). This supports the possibility that inflammation and reduced autophagy can be present before clear symptoms start, although the study was small and cross-sectional. [10]

In a proof-of-concept lab study using urinary extracellular vesicles (tiny particles released by cells) from 10 adults with Fabry disease, these vesicles caused recipient cells to build up Gb3 and later showed changes consistent with impaired autophagy. This suggests one possible way disease-related signals might spread between cells, but it was done in cells in the lab rather than in patients. [11]

A mouse study tested ways to engineer the GLA gene so the liver would secrete more alpha-Gal A enzyme after AAV-based gene therapy. The modified designs increased enzyme activity and strongly reduced Lyso-Gb3 levels in blood and tissues in Fabry mice, with the strongest results when both codon optimization and a different signal peptide were used. This is preclinical work, so it shows what happened in mice and does not yet tell us what results would look like in humans. [12]

For patients, these studies mainly add to the scientific picture of what may be happening early in Fabry disease and what future therapies are trying to fix. What became clearer is that signs of inflammation and changes in autophagy can show up even before symptoms in some children, and that patient-derived urinary particles can carry signals that change lipid handling in lab cells. What remains uncertain is how these early signals relate to future symptoms in individuals, and how quickly preclinical gene therapy improvements can translate into safe and effective human treatments. [10] [11] [12]

This month’s case reports mostly served as cautionary or practical examples rather than broad evidence about typical Fabry disease outcomes. They showed that Fabry can mimic other conditions on certain tests, and they described one example of a surgical anesthesia approach used successfully in a person with Fabry and lung disease. Because each report describes a single patient, these findings illustrate possibilities and pitfalls rather than setting expectations. [5] [13]

One report described intense myocardial uptake on bone scintigraphy in a person with Fabry disease, which could be mistaken for cardiac amyloidosis on that type of scan. This reinforces that scan results may need confirmation with other tests when the appearance is not specific. [5]

Another report described a woman with Fabry disease and significant breathing problems who had umbilical hernia repair under spinal anesthesia without reported respiratory, neurologic, or hemodynamic complications. The case suggests neuraxial anesthesia can be feasible for some Fabry patients when carefully planned and monitored, but it does not show how often this would be appropriate in others. [13]

For patients and caregivers, these reports mainly help set realistic expectations about uncertainty in interpreting specialized tests and the importance of individual planning around procedures. What became clearer is that Fabry disease can create test results that resemble other diseases on some scans, and that at least one person with Fabry and respiratory comorbidity underwent abdominal wall surgery with spinal anesthesia smoothly. What remains uncertain is how often these situations occur and how well these experiences apply to different Fabry phenotypes or medical histories. [5] [13]

One study this month focused on improving how quality of life is measured in adults with Fabry disease rather than on a new treatment or test. The main finding was that the Adult Fabry Disease Quality of Life scale (AFQOL) gave very consistent results when the same people completed it twice about 2 weeks apart. This supports AFQOL as a stable way to measure patient-reported quality of life in research settings, while leaving open questions about how to interpret meaningful change over time. [14]

In Japanese adults with Fabry disease, AFQOL scores showed high test-retest reliability and strong internal consistency. The study could not determine a minimal important change, meaning it was not able to define how big a score change would feel meaningful to a patient using their chosen anchor question. This is a common next step in validating questionnaires and will likely require larger or longer studies. [14]

For patients, this does not change care directly, but it supports better research that includes lived experience in a consistent way. What became clearer is that AFQOL appears reliable over short periods, so differences seen in studies are less likely to be random noise from the questionnaire itself. What remains uncertain is how to translate score changes into everyday meaning, because a clear threshold for a meaningful change was not established in this study. [14]